

Clinical Commissioning Policy: Lymphovenous Anastomosis (LVA) Microsurgery for Primary and Secondary Lymphoedema

Document	Dr Geoffrey Carroll, Mr Amar Ghattaura,					
Authors:	Melanie Thomas,					
	Dr Phil Webb, Kamala Williams, Dominique					
	Gray Williams					
Executive Lead:	Medical Director WHSSC					
Clinical Evidence	Evidence Appraisal by Medical Directorate					
and Evaluation	and Prioritisation Panel					
Group						
Approved by:	Joint Committee					
Issue Date:	01/08/2015					
Review Date:	01/12/2024					
Document No:	CP87b					

Document History

Revision History							
Version No.	Revision date	Summary of Changes	Updated to version no.:				
0.1	27/04/2015	Inclusion criteria from Business case Exclusion criteria Additional outcome measures form Business case	0.2				
0.2	27/04/2015		0.3				
0.3	May 2015	Addition of referral form, assessment form, pathway etc by Melanie Thomas	0.4				
0.4	15/05/2015	Addition of definition, OPCS4 codes, BSL Grouping measurement inclusion criterion, clarification of age related criterion removal of duplicate information from body of text to Annex	0.5				
0.5	17/06/2015	Change to age criteria – adult only policy Referral via nominated clinical gatekeeper in local Lymphoedema services only.	0.6				
0.6	25/06/2015	Consultation section updated to include Management Group	0.7				
0.7	07/07/2015	Approved by Joint Committee	1.0				
Date of nex	t revision	December 2024					

Consultation		
Name	Date of Issue	Version
		Number
Lymphoedema team: Mr Ghattaura and WHSS	22/04/15	0.2
Commissioners K Williams/D Gray-Wiliams		
A Ghattaura, M Thomas, J Fitzpatrick	27/04/15	0.3
All above	28/04/15	0.4
Dr Carroll and K Williams	14/05/15	0.5
Formal consultation	17/06/15	0.6
Management Group	24/06/15	0.6
Joint Committee	07/07/15	0.7

Approvals					
Name	Date of Issue	Version No.			
Joint Committee	01/08/2015	1.0			

Distribution – this document has been distributed to							
Name By Date of Issue Version No.							

Policy Statement

Background

Lymphoedema is a chronic disease caused by impairment of the lymphatic transport capacity, resulting in oedema, excess of tissue proteins, and in later stages, inflammation and irreversible changes such as fibrosis, excess accumulation of adipose tissue and skin fragility. Additionally, lymphoedema patients have a higher risk of developing cellulitis due to the high protein concentration.

Lymphoedema is a progressive chronic condition that affects a significant number of people (estimated at 9,500 in Wales). The disease can have deleterious effects on patient's physical and psychological health. Even though the impact can be greatly ameliorated by appropriate management, many patients receive inadequate treatment and several systematic reviews have highlighted the distinct lack of evidence for the optimal treatment of lymphoedema. Traditional lymphoedema therapeutic treatment incorporates skin management, movement and exercises, compression therapy including multi layer lymphoedema bandaging and compression garments as well as manual lymphatic drainage (medical massage therapy).

<u>Epidemiology of the Current Lymphoedema</u> <u>Network Wales Case Load:</u>

Congenital and Hereditary Lymphoedema: 7% Secondary Lymphoedema 93%

Lower Limb 66% (80% of these bilateral)

Upper limb 34%

Male 23%: Female 77%

Age <18 1%

18-35 3%

36-54 28%

55-74 40%

75+ 28%

Lymphovenous Anastomosis (LVA) has been performed for patients with peripheral lymphoedema since 1977. Several authors have since applied LVA in several variations of end-

to-end or end-to-side, or both, and have described long-term results of LVA in circumferential and volume reduction, or both, of the affected limbs.

As an improvement over the original technique of end-to-end anastomosis, researchers have been performing lymphaticovenous side-to-end anastomosis (LVSEA) between the sidewall of the lymphatics and the proximal stump of the vein for patients with chronic peripheral lymphoedema since 1998. From the perspective of lymph flow in the anastomosed lymphatics, LVSEA can divert the obstructed lymph flow and decompress lymphatic hypertension to the same extent as conventional LVA, in addition to theoretically preserving the original flow even if anastomosis becomes obstructed, possibility that should not be ignored in patients with a limited number of functional lymphatic vessels.

Although the evidence base for LVA is limited and appraised as low grade, the data available appears to provide consistent quantitative improvements postoperatively, with a relatively wide safety margin with little evidence of serious adverse events or post-operative complications. [However, well-designed head-to-head comparisons between different surgical approaches are needed to evaluate this further.]

Little evidence is available on quality of life or cost effectiveness for LVA.

Summary of Access Criteria

<u>Inclusion Criteria for LVA Scanning and Assessment</u>

- 1. Diagnosed with primary or secondary lymphoedema affecting upper or lower limbs
- 2. Patients must be diagnosed with Mild to Moderate Lymphoedema this includes:
- Maximum of 20% excess volume difference on circumferential measurement between affected and non affected limb;
- Limb shape is normal up to a maximum distortion of Distal: Proximal (DP) ratio of 0.2. (A similar amount of oedema should be

present in both the proximal and distal segments of a limb);

- Tissues must be soft with no evidence of fibrosis, no skin creases or folds;
- There must be no wounds, ulcers, lymphorrhoea or hyperkeratosis present.
- 3. International Society of Lymphology(ISL) Staging of 0-2 and British Lymphology Society (BSL) Grouping measurement of 1-2;
- 4. Average of 2 cellulitis infections per annum requiring antibiotic treatment;
- 5. BMI equal to or lower than 30;
- 6. Concordance to lymphoedema self management treatment plans including daily skin care, movement and exercise, compression therapy and self massage;
- 7. Fragility Marker (patients must be able to complete a timed up and go test from sitting in a chair, stand up, walk 3 meters, turn around, walk back and sit down within 13.5 seconds);
- 8. Patient to be non smoking for a minimum of 2 months before the procedure with a commitment to continue smoking abstinence for at lease 1 month post surgery.

Eligibility for LVA surgery

- 1. All criteria for LVA scanning and assessment is approved
- 2. On the Indocyanine Green (ICG) Pulsion Lymphatic Imaging System scans;
 - Linear lymphatics must be noted
 - If Linear and Splash are noted case is discussed with MDT
 - No Stardust or Diffuse lymphatics should be accepted for LVA Surgery
- 3. Patients must be classed medically fit for anaesthesia

Exclusion Criteria

- 1. Pregnant
- 2. Active cancer disease
- 3. Untreated fungal infections
- 4. Previous anaphylaxis to dye injections
- 5. Patient does not fulfil smoking cessation criterion.
- 6. BMI of 31 or more
- 7. Medical conditions

- a. Renal impairment
- b. Urenia
- c. Liver disease

Responsibilities

Referrers within the Lymphoedema pathway including the screening programme should:

- Inform the patient that this treatment is not routinely funded outside the clinical and patient selection criteria in this policy; and
- Refer to the National Lymphoedema Clinicians based in Cimla Hospital Neath only via the agreed screening and surgery pathway

The Lymphoedema team including plastic surgeon considering treatment should:

- Discuss all the alternative treatments with the patient;
- Advise the patient of any side effects and risks of the potential treatment;
- Inform the patient that treatment is not routinely funded outside of the criteria in the policy;

Confirm that there is contractual agreement with WHSSC for the treatment.

Abbreviations and Glossary

ABPI - ankle brachial pressure index

CDT - Complex decongestion therapy

IPC – intermittent pneumatic compression

LVA- Lymphovenous anastomosis

LVL – Lymphovenous-lymphatic transplant

MILS - Minimally invasive lymphatic supermicrosurgery

MLD - Manual lymphatic drainage

MLLB - Multi-layered inelastic lymphoedema bandage

SLD – simple lymphatic drainage

TBPI – toe-brachial pressure index

Table of Contents

1. Aim	10
1.1 Introduction	rvice Specifications10
2.1 Definition	11 11
3.1 Clinical Indications	d Assessment12 13 13
3.3 Referral Pathway	14
4.1 Clinical Outcome and Quality Measures 4.1.2 Quality of Life	
Referral Pathway	Annex 119
Annov 2	20

1. Aim

1.1 Introduction

The document has been developed as the policy for the planning of Welsh patients. The policy applies to residents of all seven Health Boards in Wales.

The purpose of this document is to:

- Specify the clinical circumstances under which patients will be able to access Lymphovenous Anastomosis (LVA) Microsurgery for Primary and Secondary Lymphoedema services;
- Clarify the referral process; and
- Define the clinical criteria that patients must meet in order to access treatment.

1.2 Relationship with other Policies and Service Specifications

This document should be read in conjunction with the following documents:

- Service Specification for LVA for Lymphoedema
- Specialised Services policies for Plastic Surgery
- All Wales Policy: Making Decisions on Individual Patient Funding Requests (IPFR).

2. Scope

2.1 Definition

Lymphovenous Anasatmosis (LVA) is a super micro vascular surgical technique in which a damaged lymphatic vessel is connected to a small vein permitting lymph fluid to drain directly into the blood stream and thereby reducing swelling in the tissues.

The aim of LVA microsurgery is to reduce the symptoms associated

with mild to moderate primary or secondary lymphoedema.

2.2 Codes

ICD-10 Codes

Code	Code	Description
Category		-
N/A	N/A	N/A

OPCS 4 Codes

Code Category	Code	Description
	T928	Operation on lymphatic tissue
	T892	Bypass of obstruction of lymphatic duct

HRG Codes

Code Category	Code	Description
WA34	WA2AZ	Procedures on the lymphatic system

2.3 Exception to the Policy

Given the agreed evaluation and defined nature of patient treatment within the screening evaluation it is not anticipated that there will be exceptions to the policy.

3. Access Criteria

3.1 Clinical Indications

Upper-extremity lymphoedema most often occurs after breast cancer; lower-extremity lymphoedema most often occurs with

uterine and vulval cancer, prostate cancer, lymphoma or melanoma. Other causes of lymphoedema affecting the upper or lower limbs maybe primary or secondary but not related to cancer.

Specialist investigations to select patients will be carried out. These may include:

- **Ultrasound** to assess tissue characteristics for skin thickening and fibrosis
- **Colour Doppler ultrasound** to exclude deep vein thrombosis and evaluate venous abnormalities
- Lymphoscintigraphy to identify lymphatic insufficiency in patients where the case of the swelling in unclear, to differentiate lipooedma and lymphoedema and to evaluate potential candidates for surgery. Quantative lymphoscintigraphy involves a dynamic (exercise) component in addition to static testing and provides additional information on lymphatic transportation.
- Micro-lymphangiography using fluorescein labelled human albumin – to assess dermal lymph capillaries
- Indirect lymphography using water soluble contract media – to opacify initial lymphatics and peripheral lymph collectors and to differentiate lipooedma and lymphoedema
- CT/MRI scan the detect thickening of the skin and the characteristic honeycomb pattern produced by lymphoedema to detect lymphatic obstruction at the root of a limb or in the pelvis or abdomen and to differentiate lipooedma and lymphoedema
- Indocyanine green-enhanced lymphography evaluating extremity lymphoedema, severity scaling and diagnosis. This is a non-invasive test that allows real-time evaluation and unlike lymphoscintigraphy, it poses no risk of radiation exposure.

The Welsh Screening programme will be based on specific methods:

3.1.1 Inclusion Criteria for LVA Scanning and Assessment

- Diagnosed with primary or secondary lymphoedema affecting upper or lower limbs
- 2. Patients must be diagnosed with Mild to Moderate Lymphoedema this includes
 - maximum of 20% excess volume difference on circumferential measurement between affected and non affected limb
 - Limb shape is normal up to a maximum distortion of Distal: Proximal (DP) ratio of 0.2. (A similar amount of oedema should be present in both the proximal and distal segments of a limb).

- Tissues must be soft with no evidence of fibrosis, no skin creases or folds
- There must be no wounds, ulcers, lymphorrhoea or hyperkeratosis present
- 3. International Society of Lymphology (ISL) Staging of 0-2 and British Lymphology Society (BSL) Grouping measurement of 1-2.
- 4. Average of 2 cellulitis infections per annum requiring antibiotic treatment
- 5. BMI equal to or lower than 30
- 6. Concordance to lymphoedema self management treatment plans including daily skin care, movement and exercise, compression therapy and self massage
- 7. Fragility Marker (patients must be able to complete a timed up and go test from sitting in a chair, stand up, walk 3 meters, turn around, walk back and sit down within 13.5 seconds) (Podsiaolo 1991)
- 8. Patient to be non smoking for a minimum of 2 months before the procedure with a commitment to continue smoking abstinence for at lease 1 month post surgery.

3.1.2 Inclusion criteria for LVA surgery

- 1. All criteria for LVA scanning and assessment is approved
- 2. On the Indocyanine Green (ICG) Pulsion Lymphatic Imaging System scans;
 - Linear lymphatics must be noted
 - If Linear and Splash are noted case is discussed with MDT
 - No Stardust or Diffuse lymphatics should be accepted for LVA Surgery
- 3. Patients must be classed medically fit for anaesthesia
- 4. All patients aged 18 or above are covered by this policy. Adult Lymphoedema patients must meet all the criteria for surgery.

3.1.3 Exclusion Criteria

- 1. Pregnant
- 2. Active cancer disease
- 3. Untreated fungal infections
- 4. Previous anaphylaxis to dye injections
- 5. Patient does not fulfil smoking cessation criterion.
- 6. BMI of 31 or more
- 7. Medical conditions
 - a. Renal impairment
 - b. Urenia
 - c. Liver disease

Please see Annex 2 for Referral Screening Assessment Form.

3.2 Stopping Criteria

N/A

If the patient does not meet the criteria for treatment, but the referring clinician believes that there are exceptional grounds for treatment, an Individual Patient Funding Request (IPFR) can be made to WHSSC under the <u>All Wales Policy for Making Decisions on Individual Patient Funding Requests (IPFR)</u>.

If the patient wishes to be referred to a provider out of the agreed pathway and the referring clinician believes that there are exceptional grounds for treatment at an alternative provider, an Individual Patient Funding Request (IPFR) can be made to WHSSC under the <u>All Wales Policy for Making Decisions on Individual Patient Funding Requests (IPFR)</u>.

Guidance on the IPFR process is available at www.whssc.wales.nhs.uk

3.3 Referral Pathway

Please see Annex 1 for referral pathway

3.4 Responsibilities

Referrers should:

- Inform the patient that this treatment is not routinely funded outside the criteria in this policy; and
- Refer via the agreed pathway

Clinician considering treatment should:

- Discuss all the alternative treatment with the patient;
- Advise the patient of any side effect and risks of the potential treatment;
- Inform the patient that treatment is not routinely funded outside of the criteria in the policy; and
- Confirm that there is contractual agreement with WHSSC for the treatment.

4. Quality and Safety

4.1 Clinical Outcome and Quality Measures

4.1.1. Clinical outcomes

Range of Movement:

- 1. Excess volume reduction % versus pre and post operative (at 6, 12, 24 months post surgery)
- 2. Absolute volume reduction % versus pre and post operative (at 6, 12, 24 months post surgery)
- 3. Number of episodes of cellulitis post surgery (compared to pre-surgical history)
- 4. No improvement post-operation %
- 5. Pre-operative antibiotic prophylaxis % with target of 100% (patients currently on prophylaxis antibiotics will be stopped post surgery)
- 6. Number of Lymphoedema management appointments at local Lymphoedema health Board required after surgery (versus number required pre LVA Surgery)
- 7. 70% of LVA patients will stop utilising compression garments
- 8. Timed up and go improvement % from pre to post operative
- 9. Decrease in discomfort and pain pre versus post surgery

Visual analogue scale (0-10). Rate your pain and then heaviness of your lymphoedema limb using the scale below:

	0 (nothing)	10 (excruciating)
Pain (0-10):	<u>H</u> eaviness (0-10):
10. Range of surgery	of Movement % improvement pre	evious versus post
Objective Ass	sessment	

			RIGHT			LEFT					
		100	75	50	25	0%	100	75	50	25	0%
		%	%	%	%		%	%	%	%	
Shoulde	Hip										
r											
Elbow	Kne										
	е										
Wrist	Ankl										
	е										
Fingers	Toes										
Additiona	l Info:		I		I			I	I	I	1

Complications

- 1. Operative-site infection % with target less than 4.7 percent
- 2. Lymphorrhea % with target less than 7.7 percent
- 3. Re-exploration for flap congestion with target less than 2.7 percent
- 4. Additional procedures. Target less than 22.6 percent

4.1.2 Quality of Life

Evidence of improved health benefit on Quality of Life scales including ambulation and mobility, pain, patient satisfaction

A qualitative study will be undertaken with patients who are eligible and non eligible in the effect of LVA on quality of life, see Annex 2.

4.1.3. Clinical Audit Programme

Agreed international comparisons with equivalent LVA surgical programmes and measures as specified in section 4.1.

4.1.4. Measuring costs of surgery including investigations and post-operative medical and later surgical care

As Part of work undertaken by the University of Swansea Socio economic Health evaluation of Lymphoedema Network Wales a

service model has been developed which will be able to account for potential savings to be met by patients having the LVA surgery.

4.2 Quality Standards

ABMUHB Plastic Surgery service must work to written quality standards and provide monitoring information to WHSS as the lead commissioner.

The centre at ABMUHB must enable the patient's, carer's and advocate's informed participation and to be able to demonstrate this. Provision should be made for patients with communication difficulties.

4.3 Patient Experience

Providers should use a validated patient experience tool for monitoring patient experience on, as a minimum, an annual basis (e.g. CAREs tool (http://www.caremeasure.org/).

Patient experience will be included in the departmental audit programme. The LVA service will be fully evaluated including an indepth qualitative interview.

4.4 Putting Things Right: Raising a Concern

Whilst every effort has been made to ensure that decisions made under this policy are robust and appropriate for the patient group, it is acknowledged that there may be occasions when the patient or their representative are not happy with decisions made or the treatment provided. The patient or their representative should be guided by the clinician, or the member of NHS staff with whom the concern is raised, to the appropriate arrangements for management of their concern:

- When a patient or their representative is unhappy with the decision that the patient does not meet the criteria for treatment further information can be provided demonstrating exceptionality. The request will then be considered by the All Wales IPFR Panel.
- If the patient or their representative is not happy with the
 decision of the All Wales IPFR Panel the patient and/or their
 representative has a right to ask for this decision to be
 reviewed. The grounds for the review, which are detailed
 in the All Wales Policy: Making Decisions on Individual
 Patient Funding Requests (IPFR), must be clearly stated.
 The review should be undertaken, by the patient's Local
 Health Board;

• When a patient or their representative is unhappy with the care provided during the treatment or the clinical decision to withdraw treatment provided under this policy, the patient and/or their representative should be guided to the LHB for NHS Putting Things Right. For services provided outside NHS Wales the patient or their representative should be guided to the NHS Trust Concerns Procedure, with a copy of the concern being sent to WHSSC.

5. Equality Impact and Assessment

The Equality Impact Assessment (EQIA) process has been developed to help promote fair and equal treatment in the delivery of health services. It aims to enable Welsh Health Specialised Services Committee to identify and eliminate detrimental treatment caused by the adverse impact of health service policies upon groups and individuals for reasons of race, gender re-assignment, disability, sex, sexual orientation, age, religion and belief, marriage and civil partnership, pregnancy and maternity and language (welsh).

This policy has been subjected to an Equality Impact Assessment. *The Assessment identifies the potential for adverse impact or missed opportunities to promote equality.

A decision was made to proceed with the policy because Welsh Government have determined that the Lymphoedema screening programme which has commenced must be supported by a surgical LVA programme with the requirement for geographical equity balanced against patient selection criteria for defined access to surgery.

Referral Pathway

Annex 1

Flow diagram of LVA Referral and Assessment Process

REFERRALS

Designated local gatekeepers Lymphoedema Clinics

National Lymphoedema Posts (NLP)

National Lymphoedema Office Cimla Hospital, Neath.

SCREENING ASSESMENT Assess eligibility for LVA screening on referral form- if not contact referrer and patient explaining unsuitability.

SURGERY Within 36 weeks If patient meet criteria offered a screening appointment within 18 weeks of referral in

- Cimla Hospital
 - Tenovus Cancer Care mobile Unit
 - Local Health Board hospital

Lymphatics suitable for LVA Surgery

Full explanation given to patient and report sent to Amar Ghattura (AG) for MDT case conference. Full report sent to patients, GP and Lymphoedema Clinic

Lymphadics not suitable for LVA surgery

Full explanation given to patient. A full report sent to patient, GP and Lymphoedema Clinic. Patients continues on current treatment pathways for lymphoedema

Appointment Arranged with AG and patient. This may be in person or via Microsoft Lync via local lymphoedema clinic.

Pre- operative assessment in Morriston Hospital or local hospital-Assessment form completed as per protocol taken by NLP

Day Case Surgery- measurements taken preoperatively by NLP

1 Week Review - AG and NLP

2 week Review NLP (stitches removed)

1/12, 3/12, 6/12, 9/12 Review NLP

12/12 Review NLP & AG

18/12, 24/12, 36/12, 48/12, 60/12 Review NLP

Checklist

CP087b: Lymphovenous Anastomosis (LVA) Microsurgery for Primary and Secondary Lymphoedema

A Screening Referral Form should be completed by the referring gatekeeper (Lymphoedema Screening Service) or by the treating clinician Mr Amar Ghattaura for every patient referred:

- i) Where the patient meets the criteria AND the procedure is included in the SLA (contract) for Plastic Surgery at ABMUHB AND the referral is received by the agreed centre at Singleton/Morriston Hospital, the form should be completed and retained by the receiving centre for audit purposes.
- ii) The patient meets the criteria **AND** is received at an agreed centre, but the procedure is not included in the contract. The Screening Referral Form must be completed and submitted to WHSSC for prior approval to treatment.
- iii) **Not applicable**: The patient meets the criteria but wishes to be referred to a non contracted provider. An Individual Patient Funding Request (IPFR) Form must be completed and submitted to WHSSC for consideration.
- iv) **Not applicable**: The patient does not meet criteria, but there is evidence of exceptionality. An Individual Patient Funding Request (IPFR) Form must be completed and submitted to WHSSC for consideration for treatment.

LymphoVenous Anastamosis (LVA) Screening Referral Form

Personal Information

Full Name: Enter text. NHS No: Enter text.

Address: Enter text.

DOB: Enter text. GP & Practice: Enter text.

Tel No: Enter text. Lymphoedema

Therapist: Enter text.

Email: Enter text. Health Board: Enter text.

Lymphoedema History

Location of Lymphoedema: Enter text. Lymphoedema

Type: Choose item.

Lymphoedema Side: Choose item. Dominant Side:

Choose item.

Date Lymphoedema Diagnosed: Enter text. Cause of

Lymphoedema: Enter text.

Cellulitis History

Cellulitis infections: number: Choose item.

Dates of cellulitis (2 most recent episodes): 1) Enter text.

2) Enter text.

Current Staging and Treatment:

Lymphoedema ISL Staging: Choose item. Lymphoedema BLS

Grouping: Choose item.

Lymphoedema Treatment Received: Choose item.

Past Medical History

Enter text.

Medication

Enter text.

Allergy to iodine Choose item. Other Allergies Enter

text.

Social history Smoker Choose item.	Pregnant Choose item.
BMI Enter text.	
Referrer Name: Enter text. Date of Referral: Enter text.	Job Title: Enter text.
For Office Use Only Date Referral Received: Enter tex Enter text. Appendix 2 Assessment Form LVA Personal Information	
Patient Sticker	Contact Tel No: (H)
	(mob)
	Email:
	GP Name:
GP Practice:	·····
Health Board:	
Lymphoedema History Date of lymphoedema diagnosis:	
Type of Lymphoedema: \square Property Praecox	rimary Congenital Primary
□ Primary	Tarda □ Secondary
Cause of Primary:	ilroy's Disease □ Meige's
Syndrome	
☐ Unknown ☐ Klippel-Trenaunay-\	Weber Syndrome ☐ Other:
Cause of Secondary: ☐ Trauma Inflammation	(not surgery) \square Infection \square
☐ Cancer (malig	nant/tumour) □ Cancer
(treatment)	

	□ Venous D	isease		besity	□ Lipoedema
				oility & Dep	
Upper Limb։ 🗆 Սյ					
Lower Limb: Th	nigh	□ Calf		□ Ankle	□ Foot
Affected side: □ I □ Right	_eft	□ Right		Dominant	side: □ Left
Exacerbating fact	tors:				
Improving factor	s:				
Family History of	Lymphoede	ema: □	Yes	□ No	□ N/A
Cellulitis Histor	у				
Number of Cellul	itis infection	s:			
Dates of Cellulitis	s: Episc	ode 1:		Epis	sode 2:
Cellu	ulitis caused	hospital	isati	on for:	
Episode 1: □ Yes	s □ No		N/A		
Episode 2: □ Yes	□ No		N/A	1	
Main antibiotic gi	ven for Epis	ode 1: _			_Duration:
	Ep	isode 2:			
Duration: Number of days		Episod	e 1:		Episode 2:
Prophylactic antil	biotics:□ Yes	5 	No	□ N/ <i>/</i>	Ą
	ne:				
What was the im					
a. It had n	o impact of	my day	to da	ay living	
	modify my				
	big impact	-	-	_	
d. N/A					

Medical History			
Cancer History:	□ Yes	\square No	Type:
Surgery (date / t	ype):		
Lymph Node Exci	sion: □ Yes		□ No No. removed:
No. positive:			
Radiotherapy (da	te / location	ı):	
Chemotherapy:			
Hormone Therapy	y: □ Yes	3	□ No
Other Medical His	•		
			Detail:
			Detail:
Skin condition	□ Yes	;	□ No Detail:
	,		5 . "
			Detail:
			Detail:
Liver disease	⊔ Yes	;	□ No Detail:
Paco Makor	□ Voc	□ No	Detail:
			□ N/A Detail:
Other:			
Medication:			

Allergies:					
Iodine:	□ Yes	□ No	Other:		
Social Hist	tory:				
Occupation	n:				
Smoke	□ Y	′es □ ſ	No Detail:		
Alcohol	□ Yes	□ No De	etail:		
Lymphoe	dema Ma	nagement			
Lymphoed	lema treatı	ment receive	ed (tick all re	levant):	
□ No treatExercises	ment 🗆 S	Skin Care Ac	lvice	□ Lympho	edema
☐ Simple L	ymph Dra	inage 🗆 (Compression	Garment	
□ Weight I	Manageme	nt Advice 🗆	Manual Lymp	h Drainage	□ MLLB
(including	3M)				
☐ Lymphas	ssist 🗆 De	ep Oscillatio	n Therapy	□ Kinesi	otape 🗆
Laser					
□ Other: _					
How much	n time do y	ou spend or	n completing	your self-ma	ınagement
treatment	s to mainta	ain your lym	iphoedema, i.	e. SLD, skin	care,
exercise a	nd donning	g garments?	•		
a	. nil				
b	. up to 30	minutes			
С	. up to 1 h	nour			
d	. up to 2 h	nours or mo	re		
Current ga	arment wo	rn:			
How many	/ garments	do you get	issued on av	erage per ye	ear?
				V	ersion: 1.0


Make of compression garment:	Material of garment:
□ Activa	☐ Circular Knit
□ BSN	☐ Flat Knit
☐ Haddenham Healthcare	
□ Juzo	Compression Class
(RAL):	
□ MediUK	□ ccl 1
□ Sigvaris	□ ccl 2
□ Venosan	□ ccl 3
□ Other:	_ □ ccl 4
No. of days per week you wear you	ur garment: No. of hours you
wear your garment:	
☐ One to two days	□ Nil
☐ Three to four days	□ 1-5 hours
$\hfill \square$ Five to six days	☐ 6-12 hours
□ Every day	□13 plus hours
Staging of	f Lymphoedema
ISL Staging of Lymphoedema:	BLS Grouping of
Lymphoedema:	
□ Stage 0 <i>– Latent</i>	☐ Group 0 – <i>Latent (high</i>
risk)	
□ Stage I – <i>Reversible</i>	☐ Group 1 – <i>Early Lymphoedema</i>
(LO)	
□ Stage II a – <i>Pitting</i>	☐ Group 2 – <i>Uncomplicated</i>
	(established) LO
□ Stage II b – <i>late stage II – Non-</i>	oitting □ Group 3a – Complex LO:
one limb	
□ Stage III <i>– Elephantatic</i>	☐ Group 3b – <i>Complex LO:</i>
multiple	
	limbs

□ Group 3c − Complex Midline

Lymphoedema

☐ (Group 4 – *Palliative*)

Impact of Lymphoedema1. Distress Thermometer



Using the thermometer, write down the number (0 to 10) that best describes how much distress* you have felt in the past week, including today:

* Distress is a term used to describe unpleasant feelings or emotions that may interfere with your ability to cope with kidney

failure, its physical symptoms and its treatment. Distress covers a wide range of feelings including anger, frustration, sadness, fear, depression, guilt and anxiety.

а.	How anxious does your lymphoedema make you feel?
b.	Does your lymphoedema affect your body image and sexuality?
С.	What effect does lymphoedema have on your hobbies?
d.	What effect does lymphoedema have on your work?
e.	What effect does lymphoedema have on you when shopping
	for clothes?
f.	What effect does wearing a compression garment have on
	your life?
g.	Does attending hospital appointments for your lymphoedema
	cause you concern in travel expenses?

h. On average, how healthy do you feel?
i. Have you been referred for support for anxiety? ☐ Yes ☐
No □ N/A
2. As a result of your lymphoedema, has it impacted on your
ability to work?
a. No it has no impact of my job
b. Yes I have had to modify my job
c. Yes I have had to change my job
d. Yes I have had to stop working
e. N/A
3. As result of your lymphoedema, has your financial status been
affected? □Yes □No □N/A
4. As result of your lymphoodoma, has it impacted your holidays
4. As result of your lymphoedema, has it impacted your holidays
a. No it has no impact on my holidaysb. Yes I have had to modify my holidays
c. Yes I have had to change my choice of holidays
d. Yes I have had to stop going on holidays
e. N/A
e. N/A
5. Because of your lymphoedema, how often does it make you
think of your cancer journey?
a. nil
b. every day
c. a few times a week
d. a few times a month
e. N/A

- 6. On average how many follow up visits do you attend at your lymphoedema clinic per year?
 - a. Nil
 - b. 1-2
 - c. 3-4
 - d. 5 or more
- 7. How much time do you have to take off from work or arrange childcare because of your lymphoedema e.g. for appointments, treatment, cellulitis?
 - a. Nil
 - b. 1-2 days
 - c. 3-4 days
 - d. 5 or more days
- 8. What method of transport do you use in attending hospitals due to your lymphoedema?
 - a. walk
 - b. drive in a care
 - c. catch a bus
 - d. catch a taxi
 - e. arrange an ambulance
 - f. arrange a family member/ friend to bring me
- 9. What treatment have you received from your lymphoedema service since your last appointment?
 - a. nil
 - b. MLD
 - c. Bandages
 - d. SLD
 - e. Compression garments
 - f. Other

Pre-operative Assessment

Subjective Assessment

Visual analogue scale (0-10). Rate your pain	and then heaviness of
your lymphoedema limb using the scale belo	w:

 	
0 (nothing)	10
(excruciating)	
Pain (0-10):	Heaviness (0-10):

Objective Assessment

Range of Movement:

	RIGHT				LEFT					
	100	75	50	25	0	100	75	50	25	0
	%	%	%	%	%	%	%	%	%	%
Hip										
Knee										
Ankl										
е										
Toes										
al Info:										I
	Knee Ankl e	Hip Knee Ankl e Toes	100 75 % % Hip Knee Ankl e Toes	100 75 50 % % Hip	100 75 50 25 % % % Hip Knee Ankl e Toes	100 75 50 25 0 % % % % % Hip Image: Control of the contro	100 75 50 25 0 100 % % % % % % Hip Image: Control of the	100	Toes Toes	Independent of the properties of th

Paipation:			
Skin soft	□ Yes	□ No	Detail:
Fibrosis	□ Yes	□ No	Detail:
Discolourat	ion 🗆 Ye:	5	□ No Detail:

Temperature	⊔ No	rmai 🗆 Co	ola	⊔ HOt
Stemmer's Sign	☐ Positive	□ Negative	e (pinch skin	above second
digit of hand or f	oot)			
Pitting Oedema	☐ Positive	□ Negativ	e (thumb he	ld down firmly
on tissues for 60	seconds)			
Physical Tests:				
Timed up and go	:	seconds (time taken f	or patient to
	stand from	sitting and	d walk 3 met	res and return
Photo taken:	□ Yes	□ No	Detail:	
3D photo taken:	□ Yes	□ No	Detail:	

Date:		Limb V	olume/	Moistur	isture Meter				
		Right	Left	Position	Right	Left			
Hand / Foot				A – hand / foot					
First Mark:	1			B – forearm / calf					
cm	2			C – upper arm /					
CITI	_			thigh					
	3								
Height:	4			BodyStat (Quad Sca	n			
	5			Measure	Right	Left			
	6			50kHz					
Weight:	7			200kHz					
	8			Reactant 50kHz					
	9			Unaffected/Affect					
BMI:	9			ed 5kHz					
10				> 1.139 when affe	> 1.139 when affected side is				
				dominant	dominant				
Distal Volume n	nle			> 1.066 when affected side is non-		is non-			
Distai Volume n	1113			dominant	dominant				
	1								
	2			Peron	neter				
	3			Position	Right	Left			
	4			А					
	5			В					
	6			С					
	7			D					
	8			E					
	9			F					
	10			G					
Proximal Volume	mls								
Total Volume m	nls			ICG I	mage				


Excess mls			Туре	YES	Time taken from injectio n	NO
Excess %			Linear			
Distal Volume Diff	ml	%	Splash			
Proximal Volume Diff	ml	%	Star Dust			
D/P Ratio			Diffuse			

If ICG Image Linear, how many identified?:										
Suitable for LymphoVenous Anastamosis surgery?										
□ Yes	□ Yes □ No Detail:									
	1, 3, 6, 9, 12	2,18,24, 36, 48 and 60	Month Follov	v-Up						
		Assessment								
Date	of Surgery:									
Cellu	litis Update									
Have	you had cellu	litis since your surgery?	□ Yes □ No							
	Date:									
Did th	ne Cellulitis ca	use hospitalisation? \Box	Yes □ No							
	Duration:									
Numb	er of days off	work:								
Main	antibiotic give	n:	Duration:							
Prophylactic antibiotic commenced: \square Yes \square No \square N/A										
If yes, name:										
What was the impact on your day to day living because of cellulitis?										
a. It had no impact of my day to day living										
b. I had to modify my day to day living										
			Ve	ersion: 1.0						

- c. It had a big impact on my day to day living
- d. N/A

Impact of Lymphoedema

1. Distress Thermometer



Using the thermometer, write down the number (0 to 10) that best describes how much distress* you have felt in the past week, including today:

- * Distress is a term used to describe unpleasant feelings or emotions that may interfere with your ability to cope with kidney failure, its physical symptoms and its treatment. Distress covers a wide range of feelings including anger, frustration, sadness, fear, depression, guilt and anxiety.
- a. How anxious does your lymphoedema make

	, , ,
	you feel?
b.	Does your lymphoedema affect your body image and
	sexuality?
c.	What effect does lymphoedema have on your hobbies?
d.	What effect does lymphoedema have on your work?
e.	What effect does lymphoedema have on you in shopping for
	clothes?
f.	What effect does wearing a compression garment have on
	your life?
g.	Does attending hospital appointments for your lymphoedema
	cause you concern in travel expenses?
h.	On average, how healthy do you feel?
i.	Have you been referred for support for anxiety? \square Yes $\qquad \square$
	No □ N/A
j.	Following your LVA surgery did you experience any:
	i. Bruising? $\ \square$ Yes $\ \square$ No If yes, please score

	ii.	Staining from the dye? $\ \square$ Yes	□ No	If yes, please							
		score:									
2.	. As a result of your lymphoedema, has it impacted on your ability										
	to work?										
	a.	No it has no impact of my job									
	b.	Yes I have had to modify my job									
		Yes I have had to change my job									
	d.	Yes I have had to stop working									
	e.	N/A									
2	Ac rocu	ılt of your lymphoedema, has your f	inancia	ol status boon							
٥.		d? □Yes □No □N/A	mancia	ii status been							
	arrected	I LICS LING LINA									
4.	As resu	ilt of your lymphoedema, has it impa	acted y	our holidays?							
	a.	No it has no impact on my holidays	5								
	b.	Yes I have had to modify my holida	ays								
	С.	Yes I have had to change my choice	e of ho	olidays							
	d.	Yes I have had to stop going on ho	lidays								
	e.	N/A									
	_										
5.		e of your lymphoedema, how often	does it	make you							
		f your cancer journey?									
		nil									
		every day									
		a few times a week									
	_	a few times a month									
		N/A									
6.	•	our last appointment how many follows:	ow up	sessions have							
	•	d in your lymphoedema clinic									
	a.	Nil									

- b. 1-2
- c. 3-4
- d. 5 or more
- 7. How much time do you have to take off from work or arrange childcare because of your lymphoedema e.g. for appointments, treatment, cellulitis?
 - a. Nil
 - b. 1-2 days
 - c. 3-4 days
 - d. 5 or more days
- 8. What method of transport do you use in attending hospitals due to your lymphoedema?
 - a. walk
 - b. drive in a care
 - c. catch a bus
 - d. catch a taxi
 - e. arrange an ambulance
 - f. arrange a family member/ friend to bring me
- 9. Since your LVA surgery have your travel expenses in attending hospital appointments for your lymphoedema
 - a. increased
 - b. decreased
 - c. stayed the same
 - d. not applicable
- 10. What treatment have you received from your lymphoedema service since your last appointment?
 - a. nil
 - b. MLD
 - c. Bandages

f. Other
11. No. of days per week you wear your garment:
☐ One to two days
□ Three to four days
□ Five to six days
□ Every day
12. No. of hours you wear your garment:
□ Nil
□ 1-5 hours
□ 6-12 hours
□ 13 plus hours
Subjective Assessment
Visual analogue scale (0-10). Rate your pain and then heaviness of
your lymphoedema limb using the scale below:

0 (nothing) 10 (excruciating)
Pain (0-10):Heaviness (0-10):

Objective Assessment

d. SLD

e. Compression garments

Range of Movement:

		RIGHT					L	EFT		
	100	75	50	25	0	100	75	50	25	0
	%	%	%	%	%	%	%	%	%	%
Shoul Hip										
der										

Elbow	Kne											
	е											
Wrist	Ank											
	le											
Finger	Toe											
s	S											
Addition	al Info:	l		l	I		I.	I.	I			
Palpation	<u>:</u> .											
Skin soft	□ Yes	5	\square No	Detai	l:							
Fibrosis	□ Yes	5	\square No	Detail:								
Discolour	ation	□ Yes	;	□ No	Detail	l:						
			· -									
Temperat	ture	□ Nor	mal		d		□ Hot					
Stemmer	's Sign	□ Pos	itive	□ Neg	gative	(pinch	skin a	above	seco	nd		
digit of ha	and or f	oot)										
Pitting Oe	edema	□ Pos	itive	□ Neg	gative	(thumi	b held	d dow	n firm	ly		
on tissues	s for 60	secon	ds)									
Physical T	Tests:											
Timed up	and go	:		secor	nds (tir	ne tak	en foi	r patie	ent to			
		stand	from	sitting	g and v	walk 3	metre	es, re	turn			
Photo tak	œn:		□ Yes	5	□ No		Detai	l:				
3D photo	taken:	□ Yes	;	□ No		Detail	:					
								Ve	rsion: 1	0		

Date: Limb Volume			Moisture	e Meter			
		Right Left			Position	Right	Left
Hand / Foot					A – hand / foot		
First	1				B – forearm / calf		
Mark: cm	2			_	C – upper arm / thigh		
	3						
	4				BodyStat (Quad Sca	n
Height:	5				Measure	Right	Left
	6				50kHz		
Weight:	7				200kHz		
	8				Reactant 50kHz		
BMI:	9				Unaffected/Affect		
	,				ed 5kHz		
	10				> 1.139 when a		de is
Distal Volu	ime				> 1.066 when affe	ected side	is non-
mls					domi	nant	
	1						
	2				Peron	neter	
	3				Position	Right	Left
	4				А		
	5				В		
	6				С		
	7				D		
	8				E		
	9				F		
	10				G		

D : 1							
Proximal							
Volume mls							
Total Volume							
mls							
Excess mls							
Excess %							
Distal Volume	ml	%					
Diff	ml	90					
Proximal		0/					
Volume Diff	ml	%					
D/P Ratio							
Synopsis at 24 month Follow up Date of referral for scanning: Date received by National Clinical Lead Posts: Date of scanning appointment: Date of operation of operation if suitable: 36 week target met from receipt of referral to surgery: Detail:							
Name of Patient's Health Board Scan	Health Boa performed	rd: l:					
After 2 year follow	-up, lymph	ioedema re	esolved? □ Yes□ No Detail:				
After 2 year follow		ng garmen	t? □ Yes □ No				
Detail: If yes, type	of garmer	nt worn:					